Belimumab denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for belimumab are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Applies Step Therapy to Belimumab

Belimumab (Benlysta) is a biologic B-lymphocyte stimulator (BLyS) inhibitor used in systemic lupus erythematosus (SLE) and lupus nephritis. UnitedHealthcare's step-therapy protocol for belimumab typically requires documented trials of conventional disease-modifying antirheumatic drugs (DMARDs) and/or immunosuppressants before the plan will approve a biologic. Step-therapy denials are among the most commonly overturned on appeal because patients with SLE frequently have a long prior-treatment history — the failure is usually one of documentation, not clinical reality. If the chart clearly records prior trials with dates and outcomes, the appeal is straightforward.

## Your Appeal Rights

Under ACA Section 2719 and ERISA Section 503, you have the right to a full-and-fair internal review and, if that is denied, independent external review through an accredited IRO. The external-review window is generally within four months of the final adverse benefit determination. Many states also have step-therapy override laws that require insurers to grant exceptions when a patient has already tried and failed required therapies — check whether your state's law applies to your plan type. Expedited review (72-hour decision) is available when standard timelines would jeopardize your health.

## The Appeal Process

1. Request the denial letter and UHC's step-therapy protocol for belimumab, specifying exactly which prior treatments are required and for how long. 2. Compile the complete prior-treatment history from the chart. 3. File a Level 1 internal appeal with a step-therapy exception request, attaching the documentation package. 4. If upheld, escalate to Level 2 internal review and then to external IRO. 5. If your state has a step-therapy override law applicable to your plan, cite it explicitly in the appeal.

## Documentation to Gather

• Prior-treatment history: A comprehensive list of every relevant therapy previously tried, with start date, stop date, dose changes, and the documented reason for discontinuation (inadequate response, intolerance, contraindication, or other). Dates are critical — the chart must show the trial was of adequate duration as required by UHC's protocol.
• Failure documentation: Lab results, physician notes, or standardized disease-activity scores recorded during each prior trial that demonstrate the therapy was inadequate.
• Intolerance or contraindication records: If any required step-therapy agent was not tried because of a documented intolerance or medical contraindication, include those records with the prescriber's explanation.
• Current clinical status: Recent chart notes showing disease activity that justifies escalation to a biologic.
• Medical-necessity letter: A letter from the treating rheumatologist or nephrologist that addresses each step in the UHC protocol directly, confirms it has been satisfied or explains why it cannot be, and explains why belimumab is the appropriate next therapy per the applicable ACR guideline recommendation.

## Criteria-Mapping Structure

Obtain the UHC step-therapy policy for belimumab and map every required step:

| Required Step-Therapy Agent | Date Started | Date Stopped | Documented Outcome / Reason Not Used | |---|---|---|---| | Agent A required by policy | MM/YYYY | MM/YYYY | Inadequate response per note dated X | | Agent B required by policy | MM/YYYY | MM/YYYY | Intolerance per note dated Y | | Agent C (if required) | N/A | N/A | Contraindicated per note dated Z |

Presenting this table as an exhibit to your appeal letter addresses the step-therapy requirement head-on and significantly increases the likelihood of overturn.